Sage Journals: Discover world-class research

Open access

Research article

First published 2023

Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib

Jinfeng Wang, Man Zhao, Guangjie Han [...]

Technology in Cancer Research & Treatment

Retricted access

Research article

First published 2018-01

Lenvatinib for the Treatment of Radioiodine-Refractory Thyroid Cancer in Real-Life Practice

Amandine Berdelou, Isabelle Borget, Yann Godbert [...]

Thyroid®

Retricted access

Research article

First published 2023-01

Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory,Progressive,Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study

Mijin Kim, Meihua Jin, Min Ji Jeon [...]

Thyroid®

Retricted access

Research article

First published 2025-07

Long-Term Clinical Outcomes of Patients with Differentiated Thyroid Cancer Treated with Lenvatinib: Results from Real-World Practice in Japan

Ryutaro Onaga, Tomohiro Enokida, Nobukazu Tanaka [...]

Thyroid®

Retricted access

Research article

First published 2024-12-13

Metabolic Reprogramming Contributes to Resistance Towards Lenvatinib in Thyroid Cancer

Sonam Kumari, Shilpa Thakur, Stephanie Cardenas [...]

VideoEndocrinology™

Retricted access

Research article

First published 2025-2

Reporting on Adverse Clinical Events

Clin-Alert

Retricted access

Case report

First published 2022-09-28

Neoadjuvant Combined Targeted and Immunotherapy for Unresectable Thyroid Cancer Without Anaplastic Features

Gonzalo J. Acosta, Melissa G. Lechner

VideoEndocrinology™

Search results

Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib

Lenvatinib for the Treatment of Radioiodine-Refractory Thyroid Cancer in Real-Life Practice

Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory,Progressive,Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study

Long-Term Clinical Outcomes of Patients with Differentiated Thyroid Cancer Treated with Lenvatinib: Results from Real-World Practice in Japan

Metabolic Reprogramming Contributes to Resistance Towards Lenvatinib in Thyroid Cancer

Reporting on Adverse Clinical Events

Neoadjuvant Combined Targeted and Immunotherapy for Unresectable Thyroid Cancer Without Anaplastic Features